User:Aoneonc/sandbox

Ocaratuzumab (AME-133v) is a humanized, next-generation anti-CD20 monoclonal antibody that is being developed by Mentrik Biotech, LLC. The antibody is engineered for enhanced affinity to CD20, increased antibody-dependent cell-mediated cytotoxicity (ADCC), and for improved treatment of low-affinity FcγRIIIa allotypes1.

Phase I/II trials in relapsed follicular lymphoma have been completed in the United States (US) and Japan, and a Phase I trial was conducted in US rheumatoid arthritis patients1. Phase III development in relapsed follicular lymphoma patients is underway2. Many patients relapse following currently available treatments, and a significant need for new effective treatment exists, particularly for patients with low-affinity FcγRIIIa allotypes3. In pre-clinical studies, ocaratuzumab was shown to have 13 to 20 fold greater affinity for CD20 and 6 fold more potent ADCC as compared to rituximab1,3. Additional development in other oncology and rheumatology indications will also be pursued, as well as subcutaneous formations for patient convenience2.

About Mentrik Biotech

Mentrik Biotech, LLC is a private biopharmaceutical company headquartered in Dallas, TX2. The goal of Mentrik Biotech is to optimize oncology-based therapeutics to treat patients with significant unmet medical needs2. The company aims to develop convenient, potent, and cost-effective anti-cancer molecules to enhance treatment options for patients and fulfill unmet therapeutic needs. For more information, visit www.mentrik.com2.

1 Forero-Torres, A. et al. “Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma”. Clin Cancer Res March 1, 2012 18:1395-1403; doi:1.1158/1078-0432. CCR-11-0850

2http://mentrik.com

3 Tobinai K, Ogura M, Kobayashi Y, et al. Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma. Cancer Science 2011;102:432-8.